BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

Abstract: Pulmonary arterial hypertension forms the first and most severe of the 5 categories of pulmonary hypertension. Disease pathogenesis is driven by progressive remodeling of peripheral pulmonary arteries, caused by the excessive proliferation of vascular wall cells, including endothelial cells, smooth muscle cells and fibroblasts, and perivascular inflammation. Compelling evidence from animal models suggests endothelial cell dysfunction is a key initial trigger of pulmonary vascular remodeling, which is characterised by hyperproliferation and early apoptosis followed by enrichment of apoptosis-resistant populations. Dysfunctional pulmonary arterial endothelial cells lose their ability to produce vasodilatory mediators, together leading to augmented pulmonary arterial smooth muscle cell responses, increased pulmonary vascular pressures and right ventricular afterload, and progressive right ventricular hypertrophy and heart failure. It is recognized that a range of abnormal cellular molecular signatures underpin the pathophysiology of pulmonary arterial hypertension and are enhanced by loss-of-function mutations in the BMPR2 gene, the most common genetic cause of pulmonary arterial hypertension and associated with worse disease prognosis. Widespread metabolic abnormalities are observed in the heart, pulmonary vasculature, and systemic tissues, and may underpin heterogeneity in responsivity to treatment. Metabolic abnormalities include hyperglycolytic reprogramming, mitochondrial dysfunction, aberrant polyamine and sphingosine metabolism, reduced insulin sensitivity, and defective iron handling. This review critically discusses published mechanisms linking metabolic abnormalities with dysfunctional BMPR2 (bone morphogenetic protein receptor 2) signaling; hypothesized mechanistic links requiring further validation; and their relevance to pulmonary arterial hypertension pathogenesis and the development of potential therapeutic strategies.

[1]  S. Duval,et al.  Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry , 2022, Journal of the American Heart Association.

[2]  Luman Liu,et al.  Platelet-Derived TGF (Transforming Growth Factor)-β1 Enhances the Aerobic Glycolysis of Pulmonary Arterial Smooth Muscle Cells by PKM2 (Pyruvate Kinase Muscle Isoform 2) Upregulation , 2022, Hypertension.

[3]  Jin Lin,et al.  The role of TGF-β or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis , 2021, Arthritis Research & Therapy.

[4]  M. Humbert,et al.  Sex and gender in pulmonary arterial hypertension , 2021, European Respiratory Review.

[5]  Traci L. Marin,et al.  Roles of KLF4 and AMPK in the inhibition of glycolysis by pulsatile shear stress in endothelial cells , 2021, Proceedings of the National Academy of Sciences.

[6]  Raja Chakraborty,et al.  Targeting smooth muscle cell phenotypic switching in vascular disease , 2021, JVS-vascular science.

[7]  Zulong Sheng,et al.  PTBP1 Targets ILK to Regulate the Hypoxia-Induced Phenotypic Transformation of Pulmonary Artery Smooth Muscle Cells , 2021, Drug design, development and therapy.

[8]  Michael J. Podolsky,et al.  Autoregulation of insulin receptor signaling through MFGE8 and the αvβ5 integrin , 2021, Proceedings of the National Academy of Sciences.

[9]  M. Snyder,et al.  ALDH1A3 Coordinates Metabolism With Gene Regulation in Pulmonary Arterial Hypertension , 2021, Circulation.

[10]  D. Levine Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. , 2021, The American journal of managed care.

[11]  S. Erzurum,et al.  Metabolism in Pulmonary Hypertension. , 2021, Annual review of physiology.

[12]  S. Wort,et al.  S92 Hepcidin and interleukin-6 downregulate BMPR2 and dysregulate BMPR2 downstream pathways; implications for pulmonary artery hypertension , 2021 .

[13]  M. Ghigna,et al.  Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms , 2021, Cells.

[14]  Alicia M. Salvi,et al.  Fueling the cytoskeleton – links between cell metabolism and actin remodeling , 2021, Journal of Cell Science.

[15]  Y. Urade,et al.  PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation , 2021, Science Signaling.

[16]  P. Knaus,et al.  Differential Impact of Fluid Shear Stress and YAP/TAZ on BMP/TGF-β Induced Osteogenic Target Genes. , 2021, Advanced biology.

[17]  N. Morrell,et al.  Approaches to treat pulmonary arterial hypertension by targeting bmpr2 - from cell membrane to nucleus. , 2021, Cardiovascular research.

[18]  T. He,et al.  BMP4 augments the survival of hepatocellular carcinoma (HCC) cells under hypoxia and hypoglycemia conditions by promoting the glycolysis pathway. , 2021, American journal of cancer research.

[19]  Li Linqing,et al.  Hypoxia-induced PINK1/Parkin-mediated mitophagy promotes pulmonary vascular remodeling. , 2020, Biochemical and biophysical research communications.

[20]  P. Moreira,et al.  PINK1/PARKIN signalling in neurodegeneration and neuroinflammation , 2020, Acta neuropathologica communications.

[21]  C. Rhodes The cancer hypothesis of pulmonary arterial hypertension: are polyamines the new Warburg? , 2020, European Respiratory Journal.

[22]  S. Ylä-Herttuala,et al.  BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF , 2020, Angiogenesis.

[23]  S. Archer,et al.  Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Jianping Zhao,et al.  Absence of the MFG‐E8 gene prevents hypoxia‐induced pulmonary hypertension in mice , 2020, Journal of cellular physiology.

[25]  H. Yamaguchi,et al.  A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations , 2020, Frontiers in Oncology.

[26]  C. Coman,et al.  A multi-omics analysis reveals the unfolded protein response regulon and stress-induced resistance to folate-based antimetabolites , 2020, Nature Communications.

[27]  Y. Mao,et al.  Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension , 2020, European Respiratory Journal.

[28]  K. Stenmark,et al.  RNA-Binding Proteins in Pulmonary Hypertension , 2020, International journal of molecular sciences.

[29]  K. Wagner,et al.  Context-dependent regulation of endothelial cell metabolism: differential effects of the PPARβ/δ agonist GW0742 and VEGF-A , 2020, Scientific Reports.

[30]  D. Kamp,et al.  Sphingosine Kinase 1/S1P Signaling Contributes to Pulmonary Fibrosis by Activating Hippo/YAP Pathway and Mitochondrial Reactive Oxygen Species in Lung Fibroblasts , 2020, International journal of molecular sciences.

[31]  M. Mayr,et al.  Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration , 2020, Circulation.

[32]  Li Huang,et al.  Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation , 2020, Journal of Experimental & Clinical Cancer Research.

[33]  Yanqin Cheng,et al.  LncRNA-Ang362 Promotes Pulmonary Arterial Hypertension by Regulating miR-221 and miR-222. , 2020, Shock.

[34]  G. Hansmann,et al.  Activation of The Metabolic Master Regulator PPARγ - A Potential PIOneering Therapy for Pulmonary Arterial Hypertension. , 2020, American journal of respiratory cell and molecular biology.

[35]  J. Newman,et al.  BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes. , 2019, American journal of physiology. Lung cellular and molecular physiology.

[36]  S. Li,et al.  RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer , 2019, Cancer Cell International.

[37]  K. Wagner,et al.  Vascular PPARβ/δ Promotes Tumor Angiogenesis and Progression , 2019, Cells.

[38]  P. Schumacker,et al.  Roles of HIF1 and HIF2 in pulmonary hypertension: it all depends on the context , 2019, European Respiratory Journal.

[39]  C. Ruppert,et al.  BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics , 2019, PLoS biology.

[40]  F. Cheng,et al.  Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension , 2019, Scientific Reports.

[41]  Jodie L Babitt,et al.  Ablation of Hepatocyte Smad1, Smad5, and Smad8 Causes Severe Tissue Iron Loading and Liver Fibrosis in Mice , 2019, Hepatology.

[42]  H. Aburatani,et al.  The ALK-1/SMAD/ATOH8 axis attenuates hypoxic responses and protects against the development of pulmonary arterial hypertension , 2019, Science Signaling.

[43]  T. Hla,et al.  Sphingosine 1-phosphate: Lipid signaling in pathology and therapy , 2019, Science.

[44]  M. Humbert,et al.  PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH) , 2019, Pulmonary hypertension.

[45]  Surinder Kumar,et al.  Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension , 2019, European Respiratory Journal.

[46]  M. Zhang,et al.  PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension , 2019, Proceedings of the National Academy of Sciences.

[47]  B. Himes,et al.  Genome-wide CRISPR screen identifies suppressors of endoplasmic reticulum stress-induced apoptosis , 2019, Proceedings of the National Academy of Sciences.

[48]  H. Zeng,et al.  Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease , 2018, Journal of cellular physiology.

[49]  M. Snyder,et al.  Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1–Mediated Metabolic and Epigenetic Changes , 2019, Circulation research.

[50]  Shaoliang Chen,et al.  S-nitrosation impairs KLF4 activity and instigates endothelial dysfunction in pulmonary arterial hypertension , 2019, Redox biology.

[51]  R. Derynck,et al.  Enhanced TGF-β Signaling Contributes to the Insulin-Induced Angiogenic Responses of Endothelial Cells , 2019, iScience.

[52]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[53]  Huilin Yang,et al.  S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma , 2018, EBioMedicine.

[54]  Yan-ting Zhu,et al.  SphK1/S1P Mediates PDGF-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation via miR-21/BMPRII/Id1 Signaling Pathway , 2018, Cellular Physiology and Biochemistry.

[55]  A. Hata,et al.  Bone morphogenetic protein signaling is required for RAD51-mediated maintenance of genome integrity in vascular endothelial cells , 2018, Communications Biology.

[56]  K. Mills,et al.  Enhancing the efficacy of glycolytic blockade in cancer cells via RAD51 inhibition , 2018, Cancer biology & therapy.

[57]  S. Chan,et al.  Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains , 2018, The Journal of clinical investigation.

[58]  S. Ylä-Herttuala,et al.  Differential but Complementary HIF1α and HIF2α Transcriptional Regulation. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  S. Wort,et al.  Pulmonary Arterial Hypertension: Iron Matters , 2018, Front. Physiol..

[60]  A. Al Haj Zen,et al.  MicroRNA-148b Targets the TGF-β Pathway to Regulate Angiogenesis and Endothelial-to-Mesenchymal Transition during Skin Wound Healing , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  Patty J. Lee,et al.  Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[62]  J. Voorhees,et al.  YAP/TAZ regulates TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts , 2018, Cell Communication and Signaling.

[63]  Henning Gall,et al.  Identification of rare sequence variation underlying heritable pulmonary arterial hypertension , 2018, Nature Communications.

[64]  P. Ježek,et al.  Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis , 2017, Circulation.

[65]  P. Carmeliet,et al.  Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2 , 2017, Circulation.

[66]  S. Mundlos,et al.  BMPs as new insulin sensitizers: enhanced glucose uptake in mature 3T3-L1 adipocytes via PPARγ and GLUT4 upregulation , 2017, Scientific Reports.

[67]  T. Force,et al.  Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis. , 2017, Journal of molecular and cellular cardiology.

[68]  J. Newman,et al.  Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension , 2017, Pulmonary circulation.

[69]  J. Fessel,et al.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects , 2017, European Respiratory Journal.

[70]  Pin-i Chen,et al.  Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-&bgr; in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[71]  G. Hansmann,et al.  PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. , 2017, Cell metabolism.

[72]  Nirav Shah,et al.  Novel Crosstalk between Insulin and TGF‐beta signaling in Vascular Endothelial Cells , 2017 .

[73]  J. Sheu,et al.  Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling , 2017, Scientific Reports.

[74]  S. Provencher,et al.  The cancer theory of pulmonary arterial hypertension , 2017, Pulmonary circulation.

[75]  Jamey D. Young,et al.  Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension , 2017, Pulmonary circulation.

[76]  G. Inman,et al.  TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling , 2017, Nature Communications.

[77]  W. Chung,et al.  The role of genetics in pulmonary arterial hypertension , 2017, The Journal of pathology.

[78]  J. Newman,et al.  Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. , 2016, American journal of respiratory and critical care medicine.

[79]  J. Loscalzo,et al.  Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. , 2016, The Journal of clinical investigation.

[80]  B. Jiang,et al.  Estrogen regulates miRNA expression: implication of estrogen receptor and miR-124/AKT2 in tumor growth and angiogenesis , 2016, Oncotarget.

[81]  M. Goumans,et al.  Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle , 2016, Circulation.

[82]  R. Gerszten,et al.  Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension , 2016, Circulation.

[83]  Jianhua Wang,et al.  The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis. , 2016, Carcinogenesis.

[84]  M. Bennett,et al.  Vascular Smooth Muscle Cells in Atherosclerosis. , 2016, Circulation research.

[85]  Stephen Kaptoge,et al.  BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis , 2016, The Lancet. Respiratory medicine.

[86]  Shuibang Wang,et al.  Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[87]  Liangming Liu,et al.  Role of miR-124 and miR-141 in the regulation of vascular reactivity and the relationship to RhoA and Rac1 after hemorrhage and hypoxia. , 2016, American journal of physiology. Heart and circulatory physiology.

[88]  J. Cogan,et al.  Estrogen Metabolite 16&agr;-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II–Associated Pulmonary Arterial Hypertension Through MicroRNA-29–Mediated Modulation of Cellular Metabolism , 2016, Circulation.

[89]  A. Satyanarayana,et al.  Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  M. Mcgoon,et al.  The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress , 2015, European Respiratory Journal.

[91]  S. Keshavjee,et al.  A Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human Lung , 2015, PloS one.

[92]  A. Hemnes,et al.  Fatty Acid Metabolism in Pulmonary Arterial Hypertension: Role in Right Ventricular Dysfunction and Hypertrophy , 2015, Pulmonary circulation.

[93]  S. Gräf,et al.  Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension , 2015, Nature Medicine.

[94]  M. Haigis,et al.  Intersections between mitochondrial sirtuin signaling and tumor cell metabolism , 2015, Critical reviews in biochemistry and molecular biology.

[95]  Pin-i Chen,et al.  BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension. , 2015, Cell metabolism.

[96]  A. Kenworthy,et al.  Heterozygous Null Bone Morphogenetic Protein Receptor Type 2 Mutations Promote SRC Kinase-dependent Caveolar Trafficking Defects and Endothelial Dysfunction in Pulmonary Arterial Hypertension* , 2014, The Journal of Biological Chemistry.

[97]  S. Provencher,et al.  Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. , 2014, Cell metabolism.

[98]  K. Bloch,et al.  BMP type II receptors have redundant roles in the regulation of hepatic hepcidin gene expression and iron metabolism. , 2014, Blood.

[99]  W. Wallace,et al.  Systems-level regulation of microRNA networks by miR-130 / 301 promotes pulmonary hypertension , 2022 .

[100]  M. Furuhashi,et al.  Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension. , 2014, American journal of physiology. Heart and circulatory physiology.

[101]  B. Grygiel-Górniak Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review , 2014, Nutrition Journal.

[102]  M. Eghbali,et al.  Influence of sex differences on microRNA gene regulation in disease , 2014, Biology of Sex Differences.

[103]  L. Gleaves,et al.  Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.

[104]  D. Wasserman,et al.  Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. , 2013, American journal of respiratory cell and molecular biology.

[105]  P. Tsai,et al.  Circulating microRNAs have a sex-specific association with metabolic syndrome , 2013, Journal of Biomedical Science.

[106]  Y. Suárez,et al.  MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. , 2013, Pharmacological research.

[107]  Lingying Ye,et al.  Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[108]  Kishore R. Sakharkar,et al.  Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology , 2013, Journal of drug targeting.

[109]  S. Archer,et al.  Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension , 2013, Pulmonary circulation.

[110]  W. Chung,et al.  Genetics and genomics of pulmonary arterial hypertension. , 2013, Journal of the American College of Cardiology.

[111]  J. Newman,et al.  Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[112]  L. Gleaves,et al.  A potential role for insulin resistance in experimental pulmonary hypertension , 2012, European Respiratory Journal.

[113]  J. Cailhier,et al.  MFG-E8 Released by Apoptotic Endothelial Cells Triggers Anti-Inflammatory Macrophage Reprogramming , 2012, PloS one.

[114]  R. Hamid,et al.  Pulmonary Circulation | April-june 2012 | Vol 2 | No 2 Research Ar Ticle Metabolomic Analysis of Bone Morphogenetic Protein Receptor Type 2 Mutations in Human Pulmonary Endothelium Reveals Widespread Metabolic Reprogramming Several Animal Models of Pah , 2022 .

[115]  R. Trembath,et al.  BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFβ-TAK1-MAPK pathways in PAH. , 2012, Human molecular genetics.

[116]  G. Owens,et al.  Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. , 2012, Annual review of physiology.

[117]  R. Tuder,et al.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. , 2012, American journal of respiratory and critical care medicine.

[118]  D. R. Laybutt,et al.  Inhibition of Id1 Augments Insulin Secretion and Protects Against High-Fat Diet–Induced Glucose Intolerance , 2011, Diabetes.

[119]  Howard Y. Chang,et al.  Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. , 2011, The Journal of clinical investigation.

[120]  P. Reynolds,et al.  Targeted gene delivery of BMPR2 attenuates pulmonary hypertension , 2011, European Respiratory Journal.

[121]  W. Seeger,et al.  Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension , 2011, PloS one.

[122]  J. Fessel,et al.  Oxidative injury is a common consequence of BMPR2 mutations , 2011, Pulmonary Circulation.

[123]  J. Fessel,et al.  Oxidative injury is a common consequence of BMPR2 mutations. , 2010, Pulmonary circulation.

[124]  S. Archer,et al.  Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle , 2011, Journal of Molecular Medicine.

[125]  A. Hemnes,et al.  Pulmonary hypertension in women , 2010, Expert review of cardiovascular therapy.

[126]  R. Trembath,et al.  Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension , 2010, Circulation.

[127]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[128]  E. K. Weir,et al.  Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.

[129]  J. Mitchell,et al.  The PPARβ/δAgonist GW0742 Relaxes Pulmonary Vessels and Limits Right Heart Hypertrophy in Rats with Hypoxia-Induced Pulmonary Hypertension , 2010, PloS one.

[130]  Dianqing Wu,et al.  GSK3: a multifaceted kinase in Wnt signaling. , 2010, Trends in biochemical sciences.

[131]  B. Krishnamachary,et al.  Cardiovascular , Pulmonary and Renal Pathology Hypoxia Inducible-Factor 1 Regulates the Metabolic Shift of Pulmonary Hypertensive Endothelial Cells , 2010 .

[132]  R. Speich,et al.  Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 Pathway , 2009, Circulation research.

[133]  R. Trembath,et al.  Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells* , 2009, The Journal of Biological Chemistry.

[134]  N. Morrell,et al.  Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease , 2009, Circulation.

[135]  J. Axelrod,et al.  Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt–β-catenin and Wnt–RhoA–Rac1 pathways , 2009, The Journal of cell biology.

[136]  N. Rudarakanchana,et al.  Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. , 2008, Human molecular genetics.

[137]  Jean Mosser,et al.  Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. , 2008, Blood.

[138]  R. S. Johnson,et al.  Biology of HIF-1α , 2008, Cell Death and Differentiation.

[139]  R. Trembath,et al.  Regulation of bone morphogenetic protein signalling in human pulmonary vascular development , 2008, The Journal of pathology.

[140]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[141]  A. Paterson,et al.  Genetic anticipation and breast cancer: a prospective follow‐up study , 1999, Breast Cancer Research and Treatment.

[142]  P. Carmeliet,et al.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. , 2003, The Journal of clinical investigation.

[143]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[144]  T. Bayless,et al.  Methodologic Pitfalls in the Determination of Genetic Anticipation: The Case of Crohn Disease , 2001, Annals of Internal Medicine.

[145]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[146]  S. Folstein,et al.  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. , 1995, American journal of human genetics.

[147]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.